Viridian Therapeutics (LTS:0K1R) 5-Year Yield-on-Cost %: 0.00 (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K1R Viridian Therapeutics Inc LTS:0K1R
43 GF Score
Price $22.86
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Viridian Therapeutics 5-Year Yield-on-Cost %?

Viridian Therapeutics LTS:0K1R -0.87% 43 5-Year Yield-on-Cost % is 0.00 as of Sep. 06, 2026. GuruFocus rates LTS:0K1R with a GF Score™ of 43/100 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 149 Biotechnology companies, Viridian Therapeutics ranks worse than 671140.27% on this metric.

Viridian Therapeutics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Viridian Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



LTS:0K1R's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Viridian Therapeutics  (LTS:0K1R) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Viridian Therapeutics 5-Year Yield-on-Cost % Related Terms

LTS:0K1R vs SLS, ATAI, RARE: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Viridian Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's 5-Year Yield-on-Cost % falls into.


LTS:0K1R
43GF Score
Viridian Therapeutics Inc LTS:0K1R
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Viridian Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Viridian Therapeutics (LTS:0K1R) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Viridian Therapeutics and its competitors. According to the industry distribution chart, Viridian Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Viridian Therapeutics' 5-Year Yield-on-Cost % too high?
Viridian Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Viridian Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viridian Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' 5-Year Yield-on-Cost % compare to SLS and ATAI?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Viridian Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Viridian Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viridian Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Viridian Therapeutics (LTS:0K1R) is currently considered Possible Value Trap. The current 5-Year Yield-on-Cost % is 0.00. Viridian Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Viridian Therapeutics (LTS:0K1R), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
43GF Score

Get the complete analysis for LTS:0K1R

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.86
Price